Soluble amyloid-beta isoforms predict downstream Alzheimer’s disease pathology

Cell & Bioscience

Table 2 Sample characteristics

Characteristic	CU	A−	A+	T−	T+	N−	N+
Number of individuals	318	60	50	52	58	67	43
Sex (% female)	50%	51.67%	48%	50%	50%	50.75%	48.84%
Age (y)	75.66 ± 5.22	75.37 ± 5.67	76.01 ± 4.67	73.87 ± 4.54	77.26 ± 5.32^b***	74.46 ± 4.66	77.52 ± 5.55^c**
Education (y)	15.73 ± 2.83	15.42 ± 2.68	16.1 ± 2.99	15.77 ± 2.77	15.69 ± 2.91	15.57 ± 3.1	15.98 ± 2.37
MMSE	29.08 ± 1.03	28.98 ± 1.1	29.2 ± 0.95	29.13 ± 0.93	29.03 ± 1.12	29.01 ± 1.05	29.19 ± 1.01
ADAS-Cog	6.42 ± 2.92	6.09 ± 2.91	6.81 ± 2.92	6.18 ± 2.85	6.64 ± 2.99	6.22 ± 2.69	6.73 ± 3.27
APOE ε4 carriers (%)	24.55%	11.67%	40%^a***	15.38%	32.76% ^b*	19.40%	32.56%

CU: Cognitively Unimpaired; A+: Amyloid-beta positive; A−: Amyloid-beta negative; T+: Tau positive; T−: Tau negative; N+: Neurodegeneration positive; N−: Neurodegeneration negative; y: year; MMSE: Mini-Mental State Examination; ADAS-Cog: Alzheimer’s Disease Assessment Scale-Cognitive subscale. Statistical differences for numerical characteristics were tested using t test. Statistical differences for sex and APOE status were tested using Fisher’s exact test. (^*p < 0.05, ^**p ≤ 0.01, ^***p ≤ 0.001)
^a significantly different from A−, ^b significantly different from T−, ^c significantly different from N−

ISSN: 2045-3701